RYZODEG , combination of Insulin degludec and Insulin apart (70:30) is launched and available in Mexico for the first time in world for treatment of type 2 diabetes mellitus .
As Ryzodeg is a combination product it requires fewer daily injections than administering it in separate basal and meal time insulin. Ryzodog in a multinational trial given two times daily at main meals. showed successful reduction in HbA1c with less risk of hypoglycemia(lower blood sugar).
Type 2 diabetes mellitus is a life long ,chronic disease(metabolic disorder) in which sugar(glucose) level's in blood are high (hyperglycemia) .Due to insulin resistance and lack of insulin , it is characterized by excess thirst,frequent urination and constant hunger)
Novo Nordisk,developer of Ryzodog is a global health care company with headquarters in Denmark.
As Ryzodeg is a combination product it requires fewer daily injections than administering it in separate basal and meal time insulin. Ryzodog in a multinational trial given two times daily at main meals. showed successful reduction in HbA1c with less risk of hypoglycemia(lower blood sugar).
Type 2 diabetes mellitus is a life long ,chronic disease(metabolic disorder) in which sugar(glucose) level's in blood are high (hyperglycemia) .Due to insulin resistance and lack of insulin , it is characterized by excess thirst,frequent urination and constant hunger)
Novo Nordisk,developer of Ryzodog is a global health care company with headquarters in Denmark.